H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Angion Biomedica (ANGN – Research Report) today. The company's shares closed last Monday at $0.99, close to its 52-week low of $0.98. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -37.8% and a 18.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Timber Pharmaceuticals. Currently, the analyst consensus on Angion Biomedica is a Hold with an average price target of $1.50.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-their-hold-rating-on-angion-biomedica-angn?utm_source=advfn.com&utm_medium=referral
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Angion Biomedica Charts.
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Angion Biomedica Charts.